Nanexa AB (40M) Price & Analysis

0 Followers

40M Stock Chart & Stats

€0.25

>-€0.01(-2.14%)

At close: Jan 08 4:00 PM EST

€0.25

>-€0.01(-2.14%)

Day’s Range― - ―

52-Week Range€0.12 - €0.43

Previous CloseN/A

Volume0.00

Average Volume (3M)6.00

Market Cap

€52.95M

Enterprise Value€694.15M

Total Cash (Recent Filing)€73.02M

Total Debt (Recent Filing)€987.00K

Price to Earnings (P/E)―

Beta0.93

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares Outstanding164,585,050

10 Day Avg. Volume20

30 Day Avg. Volume6

Financial Highlights & Ratios

PEG Ratio1.03

Price to Book (P/B)6.83

Price to Sales (P/S)19.19

P/FCF Ratio-26.47

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)€10.36M

Bulls Say, Bears Say

Bulls Say

Partnership/licensing Business ModelAn asset-light, partnership- and licensing-driven model creates multiple durable revenue vectors (upfronts, service fees, milestones, royalties). This diversifies cash sources across partners and program stages, reducing need for full commercial infrastructure and supporting scalable growth if deals materialize.

Proprietary PharmaShell PlatformA differentiated drug-delivery platform that enables long-acting injectables is a structural competitive advantage: it addresses a persistent clinical need (adherence, dosing frequency) and can be applied to many APIs. Platform stickiness increases partner switching costs once formulations are adopted.

Conservative Balance Sheet, Low LeverageVery low leverage and growing equity provide meaningful financial flexibility versus peers. This reduces insolvency risk while funding development or partnership programs, enabling the company to pursue R&D and collaborations without immediate refinancing pressure despite ongoing losses.

Bears Say

High Negative Free Cash FlowDeep, worsening negative free cash flow is a structural funding constraint: sustained cash burn requires external capital, which can dilute shareholders or constrain R&D cadence. Even modest operating cash improvement to date is insufficient versus large outflows, elevating financing risk over the medium term.

Ongoing Unprofitability And Weak MarginsPersistent negative operating profit and deep net losses indicate the company is not yet on a path to self-sustaining earnings. Until partnership milestones or royalties produce material revenue, profitability is unlikely, leaving performance dependent on successful deal execution and external funding.

Small Operating ScaleA very small team (13 employees) limits internal capacity to run multiple parallel development programs or large-scale partner integrations. That increases reliance on external partners and contractors, creating execution and scaling risk if multiple collaborations advance simultaneously.

Nanexa AB News

Nanexa AB’s Phase 1 Study on NEX-22A: A Potential Game-Changer for Diabetes Treatment?

Nanexa AB (($DE:40M)) announced an update on their ongoing clinical study. Study Overview: The recent clinical study by...

10M ago

40M

40M FAQ

What was Nanexa AB’s price range in the past 12 months?

Nanexa AB lowest stock price was €0.12 and its highest was €0.43 in the past 12 months.

What is Nanexa AB’s market cap?

Nanexa AB’s market cap is €52.95M.

When is Nanexa AB’s upcoming earnings report date?

Nanexa AB’s upcoming earnings report date is Aug 27, 2026 which is in 52 days.

How were Nanexa AB’s earnings last quarter?

Nanexa AB released its earnings results on Apr 29, 2026. The company reported -€0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.007.

Is Nanexa AB overvalued?

According to Wall Street analysts Nanexa AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nanexa AB pay dividends?

Nanexa AB does not currently pay dividends.

What is Nanexa AB’s EPS estimate?

Nanexa AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nanexa AB have?

Nanexa AB has 164,585,050 shares outstanding.

What happened to Nanexa AB’s price movement after its last earnings report?

Nanexa AB reported an EPS of -€0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.231%.

Which hedge fund is a major shareholder of Nanexa AB?

Currently, no hedge funds are holding shares in DE:40M

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nanexa AB

Nanexa AB (publ) is a firm dedicated to developing advanced drug delivery solutions through nanotechnology. The company leverages its proprietary PharmaShell platform, a nanobased system that utilizes atomic layer deposition (ALD) technology for drug administration. Furthermore, Nanexa is progressing NEX-18, a PharmaShell-based candidate specifically designed to address severe conditions such as Myelodysplastic Syndrome and Acute Myeloid Leukemia. The company was established in 2007 and is headquartered in Uppsala, Sweden.